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Abstract
Esophageal adenocarcinoma (EAC) is a deadly cancer with increasing incidence in the U.S., but 
mechanisms underlying pathogenesis are still mostly elusive. In addressing this question, we 
assessed gene-fusion landscapes by comprehensive RNA sequencing (RNAseq) of 55 pre-
treatment EAC and 49 non-malignant biopsy tissues from patients undergoing endoscopy for 
Barrett’s esophagus. In this cohort, we identified 21 novel candidate EAC-associated fusions 
occurring in 3.33%-11.67% of EACs. Two candidate fusions were selected for validation by PCR 
and Sanger sequencing in an independent set of pre-treatment EAC (N=115) and non-malignant 
(N=183) biopsy tissues. In particular, we observed RPS6KB1–VMP1 gene fusion as a recurrent 
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event occurring in ~10% of EAC cases. Notably, EAC cases harboring RPS6KB1–VMP1 fusions 
exhibited significantly poorer overall survival as compared to fusion-negative cases. Mechanistic 
investigations established that the RPS6KB1–VMP1 transcript coded for a fusion protein which 
significantly enhanced the growth rate of non-dysplastic Barrett’s esophagus cells. Compared to 
the wild-type VMP1 protein, which mediates normal cellular autophagy, RPS6KB1–VMP1 fusion 
exhibited aberrant subcellular localization and was relatively ineffective in triggering autophagy. 
Overall, our findings identified RPS6KB1–VMP1 as a genetic fusion that promotes EAC by 
modulating autophagy-related processes, offering new insights into the molecular pathogenesis of 
esophageal adenocarcinomas.
INTRODUCTION
The incidence of esophageal adenocarcinoma (EAC) has increased rapidly in the past few 
decades while remaining a highly morbid and mortal disease (1). In fact, EAC is now the 
most common esophageal malignancy in the United States. Despite the recognition of 
Barrett’s esophagus (BE) as a pre-malignant condition, mechanisms underlying EAC 
progression remain unclear (2). Somatic gene-fusions in cancers are being increasingly 
recognized for their potential tumorigenic roles across malignancies, and can be attractive as 
diagnostic and therapeutic molecular targets. Here we used whole-transcriptome RNA 
sequencing (RNAseq) to map and characterize transcriptionally-viable gene-fusions on a 
genome-scale in EACs.
MATERIALS AND METHODS
Detailed methods are provided as supplementary methods
Patient samples
We compiled a discovery set of 109 samples for RNAseq, consisting of 55 pre-treatment 
EACs, 49 non-malignant tissue samples, and 5 EAC cell lines. We also compiled an 
independent validation set (N=298) of 115 pre-treatment EACs and 183 normal/non-
malignant tissue samples.
Survival Analysis
Kaplan-Meier plots and survival differences were estimated using the Peto-Prentice test (3).
Whole-genome sequencing
Whole-genome sequencing was performed on FLO-1 cell line DNA. BreakDancer (4) was 
used to identify for structural/copy-number aberrations in the vicinity of the RPS6KB1–
VMP1 fusion breakpoint.
Copy-number assay
Primary tissue DNAs were evaluated for copy-number alterations using TaqMan assay for 
genes in the vicinity of the RPS6KB1–VMP1 fusion breakpoint.
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Cell lines were obtained as follows: Cos7 and CP-A cells (ATCC), HEK-293FT (Life 
Technologies), FLO-1 and SKGT4 (kindly provided by Dr. Navtej Buttar, Mayo Clinic), JH-
EsoAd1 (kindly provided by Drs. James Eshleman and Anirban Maitra, Johns Hopkins 
University School of Medicine), OE19 and OE33 (Sigma). All cell lines were obtained in 
2014 and tested for authenticity using STR genotyping, and were screened periodically for 
mycoplasma contamination.
Generation of stable CP-A cells
CP-A cells were infected with replication-deficient lentivirus to stably express full-length 
RPS6KB1–VMP1 (E1-F7, E4-E7) fusion, or tubulin beta class I (TUBB) control transcript.
Cell growth assay
CP-A cells, stably expressing each of the fusion or control gene transcripts, were assessed 
for growth over a course of 120 hours following seeding using the automated IncuCyte 
system.
Co-localization analysis of LC3A/B with RPS6KB1–VMP1 and VMP1 proteins
Cos7 cells, carrying empty vector, or V5-His containing full-length RPS6KB1–VMP1 or 
VMP1 transcript, were incubated with anti-microtubule-associated protein 1 light chain 3 
(LC3B) and anti-V5 antibodies, followed by incubation with Alexa-conjugated secondary 
antibodies and imaging using a Leica SP8 super resolution confocal microscope.
Co-immunoprecipation of Beclin1 with RPS6KB1–VMP1 and VMP1 proteins
Total cell lysates from Cos7 cells, carrying empty vector or V5-His containing full-length 
RPS6KB1–VMP1 or VMP1 transcript, were immunoprecipitated using anti-V5 agarose 
beads. Western blots were performed with anti-V5 HRP and anti-Beclin1 antibodies.
Western blot analysis of LC3A/B
Cos7 and CP-A cells expressing full-length RPS6KB1–VMP1 or VMP1 or vector/baseline 
control transcripts were grown in nutrient-depleted medium, and subsequently treated with 
30μM Chloroquine for 4 hours at 37°C. LC3A/B protein expression was subsequently 
assessed by Western blot using anti-LC3A/B antibody.
RESULTS AND DISCUSSION
Discovery of candidate gene-fusions in EACs
We used the deFuse algorithm (5) to detect putative gene-fusions in EAC and non-malignant 
tissues, included in the RNAseq discovery sample set (Supplementary Tables S1, S2, and 
S3). We identified 23 candidate EAC-associated fusion transcripts, retaining an open reading 
frame and occurring in 3.33%-11.67% of EACs (Supplementary Table S4), of which 21 
(91%) were confirmed by PCR and Sanger sequencing analyses of the fusion-junctions in 
respective samples (Supplementary Table S4), likely suggesting a false-positive rate of 9% 
in the informatics-based discovery in this study. Next, of these 21 PCR-confirmed candidate 
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fusions, we prioritized two fusions, OSBPL1A (Oxysterol binding protein-like 1A)–LAMA3 
(laminin alpha 3), and RPS6KB1 (ribosomal protein S6 kinase)–VMP1 (vacuole membrane 
protein 1) (Supplementary Fig. S1) for further studies based on the following criteria: we 
compared the 23 fusions from our study with prior whole-genome DNA sequencing studies 
in EACs reporting on structural variants (6,7), and found fusions affecting the LAMA3 gene 
to be common across the two prior (6,7) and our current study. On the other hand, 
RPS6KB1–VMP1 fusion had been previously described in breast cancers where its 
expression was found to be associated with poorer survival in breast cancer patients (8). 
Accordingly, we prioritized OSBPL1A–LAMA3 and RPS6KB1–VMP1 for further 
validation analysis. Of note, two versions of RPS6KB1–VMP1 fusion (E1-E7, E4-E7) were 
identified (Supplementary Fig. S1) by deFuse and/or by PCR-based cloning in the discovery 
EAC samples, both of which lacked the full RPS6KB1 kinase domain and encoded a 
truncated VMP1 protein.
RPS6KB1–VMP1 is a recurrent fusion in EACs with prognostic potential
Assessment of the two candidate fusions using PCR and Sanger sequencing in an 
independent set of EAC (N=115) and normal/non-malignant (N=183) tissues 
(Supplementary Table S5) revealed RPS6KB1–VMP1 (E1-E7) as a recurrent fusion present 
in 9.56% of EACs, but not detectable in normal/non-malignant tissue samples 
(Supplementary Table S6, Fig. 1B). On the other hand, the E4-E7 RPS6KB1–VMP1 isoform 
and the OSBPL1A–LAMA3 fusions were not detected in any of the EACs (Supplementary 
Table S6) or in the normal/non-malignant tissues in the validation cohort.
We next evaluated the clinical significance of the RPS6KB1–VMP1 (E1-E7) fusion by 
assessing its association with overall survival in stage III EAC patients. EAC patients 
harboring RPS6KB1–VMP1 fusion exhibited significantly poorer overall survival than 
fusion-negative patients (Fig. 1C, P=0.0084), consistent with the findings in breast cancer 
(8). Additionally, the overall survival of fusion-positive EAC patients remained poor even 
after adjusting for age at diagnosis and tumor grade using a Cox proportional hazards model 
(P=0.051), highlighting the prognostic potential of this fusion.
Potential genomic mechanisms underlying RPS6KB1-VMP1 fusion
VMP1 and RPS6KB1 genes are both localized on the same strand on chromosome 17q23.1, 
with VMP1 gene located 5’ to the RPS6KB1 gene. Given that VMP1 is the 3’ partner of the 
RPS6KB1–VMP1 fusion (Fig. 1A), it is unlikely that transcription readthrough or trans-
splicing may be the underlying causative mechanism of this fusion. Indeed, the deFuse 
algorithm suggests this fusion could be a consequence of genomic rearrangements in the 
chromosome 17q23.1 region (Supplementary Table S2), likely resulting from tandem DNA 
duplications in this chromosomal locus. Interestingly, copy-number aberrations, a 
consequence of such tandem duplication events, are frequently observed in chromosome 17q 
in EACs (9,10). Consistent with this, whole-genome DNA sequencing in the RPS6KB1–
VMP1 expressing FLO-1 (EAC-48) cell line revealed copy-number gains in the vicinity of 
RPS6KB1 and VMP1 genes (Supplementary Fig. S2). Additional qPCR-based copy-number 
analysis in a set (N=10) of fusion-positive primary EACs also revealed significant copy-
number gains in 17q23.1 genomic locus, accounting for 40% of EACs tested 
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(Supplementary Fig. S2). These findings, taken together with the prior report in breast 
cancer (8), strongly suggest that genomic rearrangements, potentially resulting from tandem 
duplications in the 17q23 locus, facilitate fusion between RPS6KB1 and VMP1 in a subset 
of fusion-positive EACs.
Protein-coding potential of RPS6KB1–VMP1 fusion transcript
We evaluated whether the RPS6KB1–VMP1 transcript indeed codes for protein or 
represents a non-coding fusion transcript. To test this, we performed Western blot analyses 
in Cos7 cells ectopically expressing the E1-E7 and E4-E7 fusion transcripts, and in FLO-1 
cells endogenously expressing the fusion transcripts (Fig. 2A), using specific antibodies 
against N- and C-terminal regions of the native RPS6KB1 protein. As expected, while the 
endogenous RPS6KB1 protein was detected using either N- or C-terminal anti-RPS6KB1 
antibodies, only the N-terminal antibody detected the fusion protein (Figs. 2B and 2C) in 
these cells. Taken together, these findings suggest that the RPS6KB1–VMP1 transcript can 
code for a fusion protein in mammalian cells. We nonetheless note that the low levels of the 
endogenous fusion protein observed in the FLO-1 cells (Fig. 2B) is consistent with the 
relatively low observed RNA read counts of the RPS6KB1–VMP1 fusion isoforms in the 
FLO-1 cell line (Supplementary Table 2).
Functional characterization of RPS6KB1–VMP1 fusion
Assessment of transforming potential of RPS6KB1–VMP1 (E1-E7) using the standard 
NIH/3T3 model did not reveal this fusion as inducing neoplastic transformation 
(Supplementary Fig. S3). This is in line with prior studies suggesting that many of the gene-
fusions identified in tumors are not sufficient to drive malignant transformation per se, and 
that additional genomic aberrations are likely required for neoplastic transformation (11). 
Given that the RPS6KB1–VMP1 fusion is detected in the FLO-1 EAC cell line, we also 
attempted to evaluate whether knock-down of the fusion transcript in FLO-1 impairs 
anchorage-independent growth. However, repeated attempts to design and induce siRNA-
mediated knock-down of the RPS6KB1–VMP1 fusion transcript in FLO-1 cells were 
technically unsuccessful. Therefore, as an alternative approach, we proceeded to functionally 
characterize this fusion using a widely-employed non-dysplastic BE cell line model (CP-A), 
especially given that the vast majority of EACs arise from BE.
We found CP-A cells stably expressing the RPS6KB1–VMP1 (E1-E7) fusion isoform to 
exhibit a significant increase in growth rate (P≪0.001), that was evident at higher cell 
densities during the later time-points (Fig. 3A). Since high cell density has been shown to be 
a potent inducer of cellular autophagy (12,13), and RPS6KB1–VMP1 encodes a truncated 
VMP1, a well-known autophagy-inducing protein (14), we hypothesized that this fusion 
may be defective in triggering cellular autophagy. We accordingly proceeded to assess the 
potential effects of this fusion on cellular autophagy processes. Given that VMP1 triggers 
the formation of autophagosmomes by recruiting LC3 (14), we speculated that the 
RPS6KB1-VMP1 fusion with a truncated VMP1 may not co-localize with LC3/
autophagosomes. Indeed, as shown in Fig. 3B, while VMP1 exhibited striking co-
localization with LC3B as distinct punctae, RPS6KB1-VMP1 fusion proteins showed a 
diffuse localization pattern. In line with this, co-immunoprecipitation studies revealed the 
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RPS6KB1-VMP1 (E1-E7) fusion as neither exhibiting interaction with Beclin1 (Fig. 3C), 
another key promoter of autophagy (14,15), nor inducing LC3A/B-II protein expression, a 
marker of active autophagy processes (15), in Cos 7 cells. This finding was independently 
confirmed in nutrient-deprived CP-A cells where TUBB showed a marked induction of the 
active LC3A/B-II protein, as compared to the RPS6KB1-VMP1 (E1-E7) fusion isoform 
(Fig. 3D). Incidentally, our observation of tubulin as a potent inducer of active LC3A/B-II 
protein (Fig. 3D) is in line with its known role in stimulating autophagy under nutrient-
deprived conditions (16). Also interestingly, cells expressing the RPS6KB1-VMP1 (E1-E7) 
isoform exhibited reduced levels of LC3A/B-I protein when compared to the controls (Fig. 
3D), suggesting that the E1-E7 fusion may additionally exert dominant-negative effects on 
cellular autophagy processes. Taken together, these findings suggest that the RPS6KB1-
VMP1 fusion may play a role in EAC pathogenesis via impairing cellular autophagy, 
resulting either from VMP1 haploinsufficiency and/or due to dominant-negative effects of 
the E1-E7 fusion on cellular autophagy processes. Further studies are warranted to delineate 
the timing and significance of autophagy pathway deregulations during EAC pathogenesis.
In summary, our study provides genome-scale characterization of transcriptionally-viable 
gene-fusions in EACs. Intriguingly, apart from the candidate EAC-associated fusions listed 
in Supplementary Table S4, our RNAseq informatics analysis also detected additional 
fusions that were present in both EAC and matched normal SQ tissues but not in normal 
gastric or unmatched BE tissues in the RNAseq dataset (Supplementary Table S7). While we 
did not prioritize such fusions in this study nor did we determine if these are selectively 
occurring in squamous tissue derived from patients with cancer, deciphering the role of these 
additional fusions in EAC pathogenesis and their potential utility as early biomarkers of 
disease progression clearly warrants separate investigation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure. 1. RPS6KB1–VMP1 fusion in EACs
(A) (Top) conserved protein domains in RPS6KB1 and VMP1, along with their length in 
amino acids (aa). (Middle) native gene exons included in the RPS6KB1–VMP1 fusion 
transcript. (Bottom) PCR amplified product spanning the E1-E7 isoform of the RPS6KB1–
VMP1 fusion-junction, along with the Sanger sequencing chromatogram of the fusion-
junction in representative EAC and matched SQ tissues used in the discovery RNAseq study. 
(B) Representative agarose gel images of RPS6KB1–VMP1 (E1-E7) fusion-junction PCR 
product from matched SQ and fusion-positive primary EAC tissue RNAs (N=11 pairs), 
included in the validation (val) cohort. Beta-2-microglobulin (B2M) was used as an 
endogenous RNA control. (C) Kaplan-Meier survival curves for Stage III EACs with or 
without the RPS6KB1–VMP1 (E1-E7) fusion.
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Figure 2. Assessing the protein-coding potential of RPS6KB1–VMP1 fusion in mammalian cells
(A) Representative gel image showing the expression of full-length RPS6KB1–VMP1 fusion 
transcripts (E1-E7, E4-E7) in FLO-1 cell line RNA. DNA ladder (L). (B) Western blot 
analysis using an N-terminal (inverted Y) anti-RPS6KB1 primary antibody in FLO-1 and 
Cos7 cells ectopically expressing full-length RPS6KB1–VMP1 fusion transcripts or vector. 
(Right) radiographic image of FLO-1 and vector-carrying Cos7 cells at ~5 minute exposure 
(Long-exposure). (C) Western blot analysis using a negative control C-terminal (inverted Y) 
anti-RPS6KB1 primary antibody in Cos7 and FLO-1 cells from above showing no detection 
of the fusion protein.
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Figure 3. Functional characterization of the RPS6KB1–VMP1 fusion
(A) (Top) effect of RPS6KB1–VMP1 fusion transcripts on CP-A cell growth. Y-axis 
represents the average confluence values of two independently-derived stable clones per 
experimental arm, with 12 replicates each, normalized to time zero (X-axis). The error bars 
represent the standard error of the means. (Bottom) PCR analyses of fusion transcripts in 
RNA derived from CP-A cells transfected with control gene (TUBB) or fusion transcripts, 
and Western blot analysis demonstrating fusion protein detection with the N-terminal anti-
RPS6KB1 antibody. (B) (Top) localization of ectopically expressed RPS6KB1–VMP1 and 
VMP1 proteins in Cos7 cells, detected by anti-V5 antibody (green fluorescence), and 
endogenous LC3B protein, a marker of autophagosome (red fluorescence). Note the diffuse 
staining pattern of RPS6KB1–VMP1 fusion protein, as opposed to the specific co-
localization of VMP1 with LC3B protein (scale bar, 10μm). (Bottom) Western blot analysis 
demonstrating the protein expression of ectopically expressed VMP1 and RPS6KB1–VMP1 
fusion in Cos7 cells. (C) Immunoprecipitation (IP) and immunoblotting (IB) analysis in 
Cos7 cells demonstrating the lack of interaction of RPS6KB1–VMP1 (E1-E7) fusion protein 
with Beclin1, as compared to the RPS6KB1–VMP1 (E4-E7) fusion or VMP1 protein. 
Western blot analysis demonstrates equivalent amounts of endogenous Beclin1 protein 
present in Cos7 total cell lysates (TCL) across treatment groups. (D) (Top) Western blot 
analysis using anti-LC3A/B antibody in Cos7 cells, following nutrient-depletion and 
chloroquine treatment, showing significant induction of LC3A/B-II product in VMP1 
expressing cells, as compared to Cos7 cells carrying the RPS6KB1–VMP1 (E1-E7) fusion. 
Also note the reduction in the protein levels of LC3A/B-I in RPS6KB1–VMP1 (E1-E7) 
expressing cells as compared to vector control. Western blot analysis demonstrates protein 
expression of ectopically expressed VMP1 and RPS6KB1–VMP1 fusion transcripts in Cos7 
cells. (Bottom) Western blot analysis using anti-LC3A/B antibody in CP-A cells, stably 
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expressing RPS6KB1–VMP1 fusion or control TUBB transcripts, after nutrient-depletion 
and chloroquine treatment. Note the significant induction of LC3A/B-II product in TUBB 
expressing CP-A cells, as compared to the CPA-cells carrying the RPS6KB1–VMP1 (E1-
E7) fusion.
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